Table 2.
Invasive fungal infection (IFI) profile during induction, its treatment and outcome
| IFI parameters | N | % |
|---|---|---|
| IFI profile during induction | ||
| Possible | 16/46 | 32.6 |
| Probable | 4/46 | 8.6 |
| Proven | Zero | Zero |
| IFI site | 20/46 | 43.4 |
| Pulmonary (HRCT chest) | 19 | 41.3 |
| PNS (CT PNS) | 1 | 2.1 |
| Total no. of GM done during the induction phase | 20/46 | 43.4 |
| Positive | 4 | 20 |
| Serum | 3 | 15 |
| BAL | 1 | 5 |
| Negative | 16 | 80 |
| Day of onset of IFI | ||
| Median (range) | 13(4–24) | |
| IFI on different antifungal prophylaxis | ||
| Posaconazole (n = 41) | 19 | 46.3 |
| Amphotericin-B (n = 4) | 1 | 25 |
| Voriconazole (n = 1) | Zero | Zero |
| IFI treatment and outcome | ||
| IFI treatment (possible + probable) | 20 | 43.4 |
| Empirical antifungal treatment | 10 | 21.7 |
| Drugs used to treat fungal infection (n = 30) | ||
| Monotherapy | 22 | 73.3 |
| Voriconazole | 4 | 18.1 |
| Amphotericin-B | 14 | 63.6 |
| Caspofungin | 4 | 18.1 |
| Double antifungal therapy | 8 | 26.6 |
| Duration of antifungal treatment (in days) | ||
| Median (range) | 12.5 (6–84) | |
| Outcome of fungal infection (n = 20) | ||
| Resolved | 12 | 60 |
| Not resolved | 4 | 20 |
| Death | 4 | 20 |
IFI invasive fungal infection, HRCT high resolution computed tomography, PNS para-nasal sinus, GM galactomannan, BAL broncho-alveolar lavage